BioCentury | Apr 14, 2020
Finance

Cerevance raises $45M toward series B, plans four more clinical programs for CNS disorders

...CVN424, from Takeda after the Japanese pharma obtained its rights through its 2012 acquisition of Envoy Therapeutics Inc....
BioCentury | Jan 25, 2018
Strategy

Takeda rides Denali’s ATV

...B (MAO-B) PD Approved in 40 countries; Phase I in Japan Undisclosed Undisclosed May 2014 Envoy Therapeutics Inc....
BioCentury | Dec 9, 2016
Company News

Novartis, Lightstone, Cerevance deal

...the Cambridge facility. Cerevance's CEO will be Brad Margus, who was CEO of CNS company Envoy Therapeutics Inc....
BioCentury | Dec 2, 2016
Financial News

Takeda, Lightstone back CNS newco Cerevance

...July 29) . Cerevance's CEO will be Brad Margus, who was CEO of CNS company Envoy Therapeutics Inc....
BioCentury | May 30, 2016
Finance

It takes a village

...appreciation for the ability of platform companies to attract non-dilutive funding. The best example is Envoy Therapeutics Inc....
BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

...phosphoinositide 3-kinase (PI3K) inhibitors, including three clinical programs. Also in 2012, Takeda acquired CNS play Envoy Therapeutics Inc....
BioCentury | May 6, 2013
Strategy

Doubling down in diabetes

...Depomed's patents covering metformin extended-release technology $10M up front; undisclosed milestones, royalties Jul-09 Terminated deals Envoy Therapeutics Inc....
BioCentury | Mar 25, 2013
Company News

Takeda, Scripps Research Institute deal

...technology to discover compounds against undisclosed targets from Takeda. In July 2010, Scripps partnered with Envoy Therapeutics Inc....
BioCentury | Dec 3, 2012
Strategy

Takeda samples, then buys

...After first making a venture investment in Envoy Therapeutics Inc. in 2009 and then sampling its wares under...
...through March, but eventually will relocate to Takeda's San Diego facility. Companies and Institutions Mentioned Envoy Therapeutics Inc....
BioCentury | Nov 12, 2012
Company News

Envoy Therapeutics, Takeda deal

...in the round were 5AM Ventures and Roche Venture Fund (see BioCentury, Oct. 18, 2010). Envoy Therapeutics Inc....
Items per page:
1 - 10 of 21
BioCentury | Apr 14, 2020
Finance

Cerevance raises $45M toward series B, plans four more clinical programs for CNS disorders

...CVN424, from Takeda after the Japanese pharma obtained its rights through its 2012 acquisition of Envoy Therapeutics Inc....
BioCentury | Jan 25, 2018
Strategy

Takeda rides Denali’s ATV

...B (MAO-B) PD Approved in 40 countries; Phase I in Japan Undisclosed Undisclosed May 2014 Envoy Therapeutics Inc....
BioCentury | Dec 9, 2016
Company News

Novartis, Lightstone, Cerevance deal

...the Cambridge facility. Cerevance's CEO will be Brad Margus, who was CEO of CNS company Envoy Therapeutics Inc....
BioCentury | Dec 2, 2016
Financial News

Takeda, Lightstone back CNS newco Cerevance

...July 29) . Cerevance's CEO will be Brad Margus, who was CEO of CNS company Envoy Therapeutics Inc....
BioCentury | May 30, 2016
Finance

It takes a village

...appreciation for the ability of platform companies to attract non-dilutive funding. The best example is Envoy Therapeutics Inc....
BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

...phosphoinositide 3-kinase (PI3K) inhibitors, including three clinical programs. Also in 2012, Takeda acquired CNS play Envoy Therapeutics Inc....
BioCentury | May 6, 2013
Strategy

Doubling down in diabetes

...Depomed's patents covering metformin extended-release technology $10M up front; undisclosed milestones, royalties Jul-09 Terminated deals Envoy Therapeutics Inc....
BioCentury | Mar 25, 2013
Company News

Takeda, Scripps Research Institute deal

...technology to discover compounds against undisclosed targets from Takeda. In July 2010, Scripps partnered with Envoy Therapeutics Inc....
BioCentury | Dec 3, 2012
Strategy

Takeda samples, then buys

...After first making a venture investment in Envoy Therapeutics Inc. in 2009 and then sampling its wares under...
...through March, but eventually will relocate to Takeda's San Diego facility. Companies and Institutions Mentioned Envoy Therapeutics Inc....
BioCentury | Nov 12, 2012
Company News

Envoy Therapeutics, Takeda deal

...in the round were 5AM Ventures and Roche Venture Fund (see BioCentury, Oct. 18, 2010). Envoy Therapeutics Inc....
Items per page:
1 - 10 of 21